BeOne Medicines (ONC) Receivables (2017 - 2026)
BeOne Medicines (ONC) posted quarterly Receivables of $938.0 million for Q1 2026, up 30.78% year-over-year from $717.2 million in Q1 2025, and up 8.43% quarter-over-quarter from $865.1 million in Q4 2025.
BeOne Medicines (ONC) Receivables (2017 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Receivables for 10 consecutive years, with $938.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables rose 30.78% year-over-year to $938.0 million; the TTM figure through Mar 2026 stood at $938.0 million (up 30.78% YoY), while the FY2025 annual figure was $865.1 million, up 27.92% from the prior year.
- Receivables advanced to $938.0 million in Q1 2026 per ONC's latest filing, from $865.1 million in the prior quarter.
- Across five years, Receivables topped out at $938.0 million in Q1 2026 and bottomed at $174.9 million in Q2 2022.
- Historically, Receivables has averaged $493.3 million across 5 years, with a median of $435.3 million in 2024.
- On a YoY basis, Receivables climbed as much as 126.25% in 2022 and fell as far as 63.9% in 2022.
- BeOne Medicines' Receivables stood at $176.2 million in 2022, then soared by 104.17% to $359.8 million in 2023, then surged by 87.98% to $676.3 million in 2024, then grew by 27.92% to $865.1 million in 2025, then advanced by 8.43% to $938.0 million in 2026.
- Business Quant data shows ONC's Receivables at $938.0 million in Q1 2026, $865.1 million in Q4 2025, and $863.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.06 Bn |
| Mar 31, 2026 | 938.02 Mn |
| Dec 31, 2025 | 865.08 Mn |
| Sep 30, 2025 | 863.28 Mn |
| Jun 30, 2025 | 770.78 Mn |
| Mar 31, 2025 | 717.24 Mn |
| Dec 31, 2024 | 676.28 Mn |
| Sep 30, 2024 | 569.05 Mn |
| Jun 30, 2024 | 529.45 Mn |
| Mar 31, 2024 | 435.29 Mn |
| Dec 31, 2023 | 359.76 Mn |
| Sep 30, 2023 | 310.71 Mn |
| Jun 30, 2023 | 301.27 Mn |
| Mar 31, 2023 | 310.96 Mn |
| Dec 31, 2022 | 176.21 Mn |
| Sep 30, 2022 | 191.37 Mn |
| Jun 30, 2022 | 174.87 Mn |
| Mar 31, 2022 | 196.10 Mn |
| Dec 31, 2021 | 488.17 Mn |
| Sep 30, 2021 | 136.81 Mn |